文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

ZDHHC12介导的紧密连接蛋白3棕榈酰化决定卵巢癌进展。

ZDHHC12-mediated claudin-3 -palmitoylation determines ovarian cancer progression.

作者信息

Yuan Meng, Chen Xiaobing, Sun Yitang, Jiang Li, Xia Zhongni, Ye Kaixiong, Jiang Hong, Yang Bo, Ying Meidan, Cao Ji, He Qiaojun

机构信息

Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

Department of Genetics, University of Georgia, Athens, GA 30602, USA.

出版信息

Acta Pharm Sin B. 2020 Aug;10(8):1426-1439. doi: 10.1016/j.apsb.2020.03.008. Epub 2020 Apr 19.


DOI:10.1016/j.apsb.2020.03.008
PMID:32963941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7488353/
Abstract

The membrane protein claudin-3 (CLDN3) is critical for the formation and maintenance of tight junction and its high expression has been implicated in dictating malignant progression in various cancers. However, the post-translational modification of CLDN3 and its biological function remains poorly understood. Here, we report that CLDN3 is positively correlated with ovarian cancer progression both and Of interest, CLDN3 undergoes -palmitoylation on three juxtamembrane cysteine residues, which contribute to the accurate plasma membrane localization and protein stability of CLDN3 Moreover, the deprivation of -palmitoylation in CLDN3 significantly abolishes its tumorigenic promotion effect in ovarian cancer cells. By utilizing the co-immunoprecipitation assay, we further identify ZDHHC12 as a CLDN3-targating palmitoyltransferase from 23 ZDHHC family proteins. Furthermore, the knockdown of ZDHHC12 also significantly inhibits CLDN3 accurate membrane localization, protein stability and ovarian cancer cells tumorigenesis Thus, our work reveals -palmitoylation as a novel regulatory mechanism that modulates CLDN3 function, which implies that targeting ZDHHC12-mediated CLDN3 -palmitoylation might be a potential strategy for ovarian cancer therapy.

摘要

膜蛋白claudin-3(CLDN3)对于紧密连接的形成和维持至关重要,其高表达与多种癌症的恶性进展有关。然而,CLDN3的翻译后修饰及其生物学功能仍知之甚少。在此,我们报告CLDN3与卵巢癌进展在[此处原文缺失相关内容]均呈正相关。有趣的是,CLDN3在三个近膜半胱氨酸残基上发生棕榈酰化,这有助于CLDN3准确的质膜定位和蛋白质稳定性。此外,CLDN3中棕榈酰化的缺失显著消除了其在卵巢癌细胞中的致瘤促进作用。通过免疫共沉淀实验,我们从23种ZDHHC家族蛋白中进一步鉴定出ZDHHC12作为一种靶向CLDN3的棕榈酰转移酶。此外,敲低ZDHHC12也显著抑制CLDN3的准确膜定位、蛋白质稳定性以及卵巢癌细胞的肿瘤发生。因此,我们的研究揭示棕榈酰化是一种调节CLDN3功能的新型调控机制,这意味着靶向ZDHHC12介导的CLDN3棕榈酰化可能是卵巢癌治疗的一种潜在策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/59f4f285c4f7/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/bd4c37008068/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/15a495c5891f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/3302a3dc08c5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/a59b19c81d65/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/873e32df6bfd/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/3b1503f0954c/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/59f4f285c4f7/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/bd4c37008068/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/15a495c5891f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/3302a3dc08c5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/a59b19c81d65/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/873e32df6bfd/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/3b1503f0954c/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33f/7488353/59f4f285c4f7/gr6.jpg

相似文献

[1]
ZDHHC12-mediated claudin-3 -palmitoylation determines ovarian cancer progression.

Acta Pharm Sin B. 2020-8

[2]
Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS-mediated mechanisms.

Cancer Sci. 2024-4

[3]
Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransferase 12 contributes to glioblastoma progression.

Ann Transl Med. 2022-3

[4]
Potential roles of claudin-3 and claudin-4 in ovarian cancer management.

J Egypt Natl Canc Inst. 2022-6-6

[5]
Visualization of a novel human monoclonal antibody against Claudin-3 for targeting ovarian cancer.

Nucl Med Biol. 2022

[6]
Regulation of the CLDN3 gene in ovarian cancer cells.

Cancer Biol Ther. 2007-11

[7]
Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.

Histol Histopathol. 2007-11

[8]
Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications.

Carcinogenesis. 2010-1-6

[9]
Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis.

Proc Natl Acad Sci U S A. 2009-3-3

[10]
Claudin-3 expression increases the malignant potential of lung adenocarcinoma cells: role of epidermal growth factor receptor activation.

Oncotarget. 2017-4-4

引用本文的文献

[1]
Recent advances in S-palmitoylation and its emerging roles in human diseases.

J Hematol Oncol. 2025-9-1

[2]
Palmitic acid and palmitoylation in cancer: Understanding, insights, and challenges.

Innovation (Camb). 2025-4-29

[3]
Potential therapeutic target in oncology: Protein palmitoylation (Review).

Oncol Rep. 2025-10

[4]
KLF5-regulated ZDHHC8 reduces chemosensitivity in high-grade serous ovarian cancer through β-catenin signaling.

Sci Rep. 2025-7-18

[5]
Role of S-palmitoylation in digestive system diseases.

Cell Death Discov. 2025-7-18

[6]
Identification of AKOS, a Chikungunya virus inhibitor, as a USP14 inhibitor for colorectal cancer treatment.

Acta Pharmacol Sin. 2025-7-17

[7]
Exploring the role of protein palmitoylation in cancer progression and therapy: a comprehensive bibliometric study (2004-2024).

Discov Oncol. 2025-7-1

[8]
Palmitoylation in cardiovascular diseases: Molecular mechanism and therapeutic potential.

Int J Cardiol Heart Vasc. 2025-4-4

[9]
VCP Promotes Cholangiocarcinoma Development by Mediating BAP1 Ubiquitination-Dependent Degradation.

Cancer Sci. 2025-6

[10]
Advances in targeting protein S-palmitoylation in tumor immunity and therapy.

Front Oncol. 2025-2-24

本文引用的文献

[1]
Measurement of co-localization of objects in dual-colour confocal images.

J Microsc. 1993-3

[2]
Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders.

Acta Pharm Sin B. 2020-4

[3]
Degradation of proteins by PROTACs and other strategies.

Acta Pharm Sin B. 2020-2

[4]
Targeting the untargetable KRAS in cancer therapy.

Acta Pharm Sin B. 2019-9

[5]
HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2.

Proc Natl Acad Sci U S A. 2019-2-28

[6]
Tight Junction in the Intestinal Epithelium: Its Association with Diseases and Regulation by Phytochemicals.

J Immunol Res. 2018-12-16

[7]
Protein palmitoylation and cancer.

EMBO Rep. 2018-9-19

[8]
The molecular era of protein S-acylation: spotlight on structure, mechanisms, and dynamics.

Crit Rev Biochem Mol Biol. 2018-7-12

[9]
Emerging Roles of DHHC-mediated Protein S-palmitoylation in Physiological and Pathophysiological Context.

Eur J Cell Biol. 2018-3-22

[10]
Stochastic palmitoylation of accessible cysteines in membrane proteins revealed by native mass spectrometry.

Nat Commun. 2017-11-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索